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Sarcomas are rare malignant tumors affecting all age groups. They are typically classified 
according to their resemblance to corresponding normal tissue. Their heterogeneous 
features, for example, in terms of disease-driving genetic aberrations and body location, 
complicate both disease classification and development of novel treatment regimens. 
Many years of failure of improved patient outcome in clinical trials has led to the conclusion 
that novel targeted therapies are likely needed in combination with current multimodality 
regimens. Sarcomas have not, in contrast to the common carcinomas, been the subject 
of larger systematic studies on how tumor behavior relates to characteristics of the tumor 
microenvironment. There is consequently an urgent need for identifying suitable molec-
ular targets, not only in tumor cells but also in the tumor microenvironment. This review 
discusses preclinical and clinical data about potential molecular targets in sarcomas. 
Studies on targeted therapies involving the tumor microenvironment are prioritized. A 
greater understanding of the biological context is expected to facilitate more successful 
design of future clinical trials in sarcoma.
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inTRODUCTiOn
Sarcomas represent rare malignant tumors of mesenchymal origin with more than 70 different entities 
(1). Multimodal treatment generally includes local control by surgery and/or radiation and systemic 
control by chemotherapy. Specific treatment protocols depend on clinical parameters, including 
stage classification, histological grade, tumor site, and subtype. Most of the sarcoma subtypes are 
relatively resistant to chemotherapy.
Diagnosis and treatment regimens should be carried out in a multidiscipline manner. It is therefore 
highly recommended that patient care is centralized to a sarcoma reference center immediately after 
the initial detection of a suspected sarcoma. The European Sarcoma Network Working Group has 
developed clinical practice guidelines for diagnosis, treatment, and follow-up in bone sarcomas (2), 
Abbreviations: ASPS, alveolar soft part sarcoma; CSF1R, colony stimulating factor 1 receptor; DFSP, dermatofibrosarcoma pro-
tuberans; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; EWS/FLI, Ewing sarcoma breakpoint 
region 1; FDA, Food and Drug Administration; FGFR, fibroblast growth factor receptor; FLT3, fms-related tyrosine kinase 3; 
GIST, gastrointestinal tumor; KIT, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; MET, hepatocyte growth 
factor receptor; PAX3-FOXO1, paired box 3-forkhead box O1; PDGFR, platelet-derived growth factor receptor; RAF, zinc 
fingers and homeoboxes 2; RANKL, tumor necrosis factor (ligand) superfamily, member 11; RECIST, response evaluation 
criteria in solid tumors; RET, ret proto-oncogene; STS, soft tissue sarcoma; TKI, tyrosine kinase inhibitor; VEGFR, vascular 
endothelial growth factor receptor; vWF, von Willebrand factor; WHO, World Health Organization.
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soft tissue, and visceral sarcomas (3), and gastrointestinal stromal 
tumors (GIST) (4).
Patient outcome is influenced by many parameters. Local 
tumor recurrence and metastatic spread at diagnosis are associ-
ated with a poor prognosis. Curative treatment options are limited 
in these patient groups. Better treatment options are also needed 
to reduce long-term complications for patients in remission. This 
is particularly important to consider in pediatric patients where 
established treatments of today are known to be associated with, 
e.g., reduced fertility later in life.
Targeted therapies are currently emerging as a promising 
complementary or alternative treatment in several pathological 
entities including GIST (5, 6). Attempts have also been made 
to identify patient subgroups that are likely to benefit from this 
novel type of treatment. Given the mechanistic nature of targeted 
therapies, a molecular target essential for disease progression of 
each individual tumor typically needs to be identified. Detailed 
knowledge on sarcoma biology is therefore important for clinical 
progress.
SUBTYPe CLASSiFiCATiOn in SARCOMA
Subtype classification in sarcoma is today guided by the 2013 
World Health Organization (WHO) classification system (7). 
Dominating soft tissue sarcoma (STS) subtypes include undif-
ferentiated pleomorphic sarcoma (UPS) and liposarcoma in 
adults and rhabdomyosarcoma in children. Also GIST is now a 
dominating subtype in adults after the inclusion in the soft tissue 
section. Common adult bone sarcomas include osteosarcoma 
and chondrosarcoma. Osteosarcoma is also a dominating subtype 
in children together with Ewing sarcoma. Examples of sarcoma 
subtypes according to their differentiation status are presented 
in Table 1.
Some of the entities are classified with the help of cytogenetics, 
or molecular genetics, searching for characteristic genetic aber-
rations including pathognomonic fusion genes. A large group of 
sarcomas is however currently being classified according to exclu-
sion criteria when a more precise categorization fails. Many of 
these tumors are referred to as UPS, or earlier, malignant fibrous 
histiocytoma. It is reasonable to assume that the classification of 
tumors belonging to this latter group will further improve with 
an increased molecular understanding.
Inconsistent classification of sarcomas has complicated 
registry-based studies, both over time and between countries. 
With increased knowledge about sarcoma biology, subtype clas-
sification is likely to rely more on molecular hallmarks in com-
bination with observations made by conventional histology and 
selected imaging assessments (9). This will allow more stringent 
analyses in defined patient groups and ultimately improve patient 
outcome.
GeneTiC ABeRRATiOnS OF COMMOn 
SARCOMA SUBTYPeS
We are only in the beginning of understanding the genetic aber-
rations involved in sarcoma development and progression. It has 
TABLe 1 | Schematic overview of sarcomas of soft and bone tissue.
Differentiation of soft tissue 
sarcomasa
examples
Adipocytic tumors Dedifferentiated liposarcoma
Fibroblastic/myofibroblastic tumors Fibrosarcoma
Smooth muscle tumors Leiomyosarcoma
Pericytic (perivascular) tumors Malignant glomus tumor
Skeletal muscle tumors Embryonal rhabdomyosarcoma
Vascular tumors Angiosarcoma
Chondro-osseous tumors Extraskeletal chondrosarcoma
Gastrointestinal tumors Gastrointestinal stromal tumor (GIST)
Nerve sheath tumors Malignant peripheral nerve sheath tumor
Tumors of uncertain differentiation Synovial sarcoma
Undifferentiated/unclassified 
sarcomas
Undifferentiated pleomorphic sarcoma 
(UPS)
Differentiation of bone sarcomasb examples
Chondrogenic tumors Chondrosarcoma grade ll–lll
Osteogenic tumors Conventional high-grade osteosarcoma
Fibrogenic tumors Fibrosarcoma
Osteoclastic giant cell rich tumors Malignancy in giant cell tumor of bone
Notochordal tumors Chordoma
Vascular tumors Angiosarcoma
Myogenic tumors Leiomyosarcoma
Lipogenic tumors Liposarcoma
Miscellaneous tumors Ewing sarcoma
Modified from the present WHO classification of tumors (8).
aDominating histotypes: UPS, liposarcoma (adults), rhabdomyosarcoma (children, 
young adults). Also GIST is now a dominating histotype in adults after the inclusion in 
the soft tissue section.
bDominating histotypes: Osteosarcoma, chondrosarcoma (adults), osteosarcoma, 
Ewing sarcoma (children, young adults).
been recognized that genetic aberrations often lead to activa-
tion of tyrosine kinase growth factor receptors (10). However, 
distinct oncogenic drivers at the molecular level are often only 
detected in subsets of a defined sarcoma entity. The histology that 
traditionally aids sarcoma subtype classification is therefore, to 
our understanding today, only partially linked to the molecular 
profile of the tumor.
Specific genetic aberrations are commonly found in the class 
of sarcomas with a simple, or close to simple, karyotype. The 
confirmed presence of disease-driving, activating mutations in 
KIT or PDGFRα in GIST can today, e.g., be used to predict tumor 
recurrence and identify patients who are likely to benefit from 
adjuvant therapy (11).
Ewing sarcoma and alveolar rhabdomyosarcoma are both 
examples of translocation-associated sarcomas. The most com-
mon translocations involve transcription factors that actively 
dysregulate gene expression. EWS/FLI in Ewing sarcoma has 
been shown to upregulate the PDGFR ligand PDGF-C (12). The 
oncogenic fusion gene PAX3-FOXO1, found in the majority of all 
alveolar rhabdomyosarcomas, has been linked to poorer patient 
outcome (13, 14). Other examples of sarcomas with specific 
genetic aberrations involving chromosomal translocations are 
synovial sarcoma, clear cell sarcoma of soft tissue, myxoid, and 
round cell liposarcoma.
Many sarcomas are, however, known to have a more complex 
karyotype. Pleomorphic undifferentiated sarcoma, pleomorphic 
and dedifferentiated liposarcoma, leiomyosarcoma, pleomorphic 
rhabdomyosarcoma, osteosarcoma, and chondrosarcoma all 
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belong to this other main class of sarcomas (10). The disease-
driving mechanisms of these tumors are likely to be related to 
defects in the cell cycle checkpoints and the genetic instability 
as such.
THe SARCOMA TUMOR 
MiCROenviROnMenT
The microenvironment of tumors is composed of multiple stro-
mal cell types and extracellular matrix proteins in addition to the 
cancer cells. The stromal compartment is typically involved in 
structural and functional support of tumor growth and coevolves 
together with the tumor cells in a unique manner depending on 
tumor type and tumor stage. It had already been described in 
1960, how a primary tumor of sarcoma can evade the anticancer 
immune response by establishing an immune-privileged micro-
environment (15, 16). In the 1970s, Juda Folkman proposed that 
angiogenesis is essential for solid tumor growth (17).
The importance of the tumor microenvironment for metastatic 
growth was addressed in the seed and soil theory (18). This theory 
describes the metastatic-prone tumor cell as “the seed” and the 
preferred metastatic site as “the soil.” Another complementary 
theory is the anatomical-mechanical hypothesis (19) suggesting 
that tumor cells are rather passively shed from the primary tumor 
by lymphatic drainage and the vascular system. This would then 
result in metastatic growth at anatomically accessible sites defined 
by the location of the primary tumor.
Both theories on the metastatic process are today considered 
applicable in a tumor-specific context (20, 21). The importance of 
tumor cell intravasation into the vascular system has particularly 
been addressed in sarcoma, where vascular invasion, as defined 
by the presence of tumor cells within any space having an 
endothelial lining, has been identified as a prognostic factor for 
metastasis (22). In the study by Engellau et al., vascular invasion 
was detected in 50 of 140 STS and was shown to closely associate 
with necrosis and malignancy grade.
Blood vessel-Associated Cells, 
Angiogenesis, and Prognostic Biomarkers
Blood vessels in tumors are composed of endothelial cells and 
various amounts of supportive mural cells including pericytes and 
vascular smooth muscle cells. The most commonly used mark-
ers for endothelial cells are CD31, CD34, VEGFR2, factor VIII, 
vWF, and endoglin. Podocalyxin was used as a vessel marker in 
experimental rhabdomyosarcoma to confirm the antiangiogenic 
response to sorafenib (23). CD31 is often considered to be a pan-
endothelial marker, whereas endoglin is expressed by activated 
endothelium. Endoglin is also expressed by tumor cells in Ewing 
sarcoma, where its expression has been shown to correlate with 
worse patient survival (24).
In 1999, Tomlinson et al. concluded that the pattern of angio-
genesis is different between sarcomas and carcinomas (25). Their 
study showed that the capillaries in carcinomas are clustered in 
bursts within the tumor stroma and that the microvessel density 
in these bursts can be used as a prognostic factor. By contrast, 
microvessel density in sarcomas was shown to have a more 
homogeneous appearance. A more recent study confirmed this 
pattern of angiogenesis showing that hot spots of angiogenesis 
were diffuse in high-grade STS and only present in 33% of the 
investigated specimens (26).
High microvessel density, as assessed by CD31 staining, 
has been shown to correlate with, e.g., high VEGF expres-
sion, tumor size ≥5 cm and high tumor grade in GIST (27). 
Microvessel density in other sarcomas has been evaluated, 
but occasionally also questioned in terms of inconsistently 
used methodologies and prognostic relevance (26, 28–32). 
Most studies on angiogenesis have chosen to focus on VEGF 
detection rather than microvessel density (33, 34). Both 
VEGF expression and circulating VEGF levels are of sug-
gested clinical relevance in sarcomas. VEGF and additional 
markers of angiogenesis in sarcomas have been reviewed 
elsewhere (33, 35, 36).
Other infiltrating Stromal Cell Types in 
Sarcoma
The importance or prognostic relevance of infiltrating stromal 
cell types in sarcomas has not been extensively characterized. 
Some functions have been associated, directly or indirectly, 
with angiogenesis or vasculogenesis. Recruited CD34+ bone 
marrow stem cells have been shown to contribute to the grow-
ing tumor vasculature in response to VEGF in experimental 
Ewing sarcoma (37). M2-like, CD163+ CD14+ macrophages 
have been described in naïve ASPS. These tumor-associated 
macrophages of myeloid origin are believed to promote tumor 
progression and possibly VEGF-mediated vasculogenesis (38). 
In contrast, M1 macrophages are typically tumor preventing 
and respond to interferon-γ (39). Cavnar et  al. recently sug-
gested that M1/M2 macrophage polarization is linked to 
oncogene activity in a mouse model of spontaneous GIST as 
well as in human GIST (40).
Several studies on patient material have brought attention 
to lymphocytes. Selected examples include a study describing 
high prevalence of tumor-infiltrating lymphocytes in STS (41). 
Others have shown that tumor-infiltrating CD3+ lymphocytes 
in GIST correlated with improved progression-free survival (42). 
Infiltration of CD8+ lymphocytes in Ewing sarcoma correlated 
with improved survival (43). Expression of immune checkpoint 
molecules, such as the T cell-suppressive receptor PD-1, has 
been correlated with disease progression in, e.g., osteosarcoma 
(44). CD20+ lymphocytes have been associated with improved 
survival in a study on STS (45).
Sarcomas are often considered to be one-compartment tumors 
harboring limited activity from infiltrating fibroblast-like cells 
(25). PDGFR+ stromal cells have been described in human 
rhabdomyosarcoma, where their presence showed a clinical 
association with subtype and metastasis (23). Frequently detected 
stromal components (osteoid, cartilage, or collagen) are however 
not likely attributed to infiltrating fibroblasts in the majority of 
sarcomas, but rather the sarcoma cells and/or the tissue-specific 
cells, themselves (46). Some investigators have suggested that 
stromal fibrosis/hyalinization is a specific pattern associated with 
a non-viable tumor following treatment in STS (47).
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THeRAPeUTiC TARGeTinG OF THe 
SARCOMA MiCROenviROnMenT
There is currently a great enthusiasm for targeted therapies as a 
novel complementary or alternative treatment method in cancer. 
A number of potential molecular targets have also been discussed 
in the context of translational sarcoma studies (48). So far, most 
phase II and phase III clinical trials where a therapeutic benefit 
has been confirmed include studies on tyrosine kinase inhibitors 
(TKIs) targeting VEGFRs, PDGFRs, and KIT. Given the mesen-
chymal origin of sarcomas, these agents are likely to target both 
tumor cells and infiltrating stromal cells in a context-dependent 
manner (Figure  1). For more details, the reader is referred 
elsewhere (36, 49). Selected agents with presumed microenvi-
ronmental effects are described below.
Therapies with Antiangiogenic effects
Angiogenesis was early predicted to be a common denominator 
for targeted therapy in a broad range of tumor types (17) and 
multiple studies have confirmed that antiangiogenic therapy 
causes starvation and reduced growth of experimental tumors. 
Accumulating evidence, however, suggest that the initial thera-
peutic benefit is followed by resistance mechanisms where the 
hypoxic and metabolic response to antiangiogenic therapy could 
worsen tumor aggressiveness (50).
One of the current antiangiogenic strategies is to alleviate 
hypoxia while improving tumor perfusion (51). Ideally, this 
approach increases response rates to radiotherapy, chemotherapy, 
and immunotherapy (5). Toxicity may however be a concern of 
some combination treatments. Of note is that the commonly 
FiGURe 1 | Potential therapeutic effects of selected TKis in sarcoma. The biological mechanisms associated with patient response to TKIs in sarcoma are 
generally poorly characterized. Imatinib has mainly been described for its ability to target aberrant PDGFR signaling in dermatofibrosarcoma protuberans (DFSP) and 
KIT (or PDGFR) in advanced GIST. Sunitinib is approved for second-line treatment of GIST, after imatinib treatment failure, with molecular targets including VEGFR, 
PDGFR, FLT3, KIT, CSF1R, and RET. Regorafenib is approved for third-line treatment of GIST, after sunitinib treatment failure, with molecular targets including 
VEGFR, KIT, RET, FGFR, PDGFR, and RAF. Pazopanib targets VEGFR, PDGFR, KIT, and RAF and is approved for use in advanced STS. Cediranib and sunitinib are 
investigated for their ability to target VEGFR signaling in, e.g., alveolar soft part sarcoma (ASPS). Imatinib and sorafenib are investigated for therapeutic use in 
chordoma, a disease with reported PDGFR activity. Sorafenib has a target spectrum, including RAF, VEGFR, PDGFR, KIT, RET, and FLT3.
targeted VEGFR pathway has not only been associated with 
induction of angiogenesis in STS but also with chemoresistance 
and regulatory T cell activity (33, 38).
The therapeutic efficacy of antiangiogenic therapy has been 
investigated in several sarcoma clinical trials. The TKI pazopanib 
was approved by the Food and Drug Administration (FDA) in 
2012 for the use in advanced STS based on the results presented 
from the PALETTE phase III study (52). Anti-tumor activity 
has been demonstrated both in terms of sarcoma cell viability 
and inhibition of angiogenesis in a sarcoma cell line-dependent 
manner (53, 54).
Imatinib is another FDA-approved TKI with established abil-
ity to target KIT-mutated advanced GISTs. VEGF activity has, 
however, been described in GIST and imatinib can suppress GIST 
VEGF expression in vitro (55). Imatinib-responding GIST patients 
also display decreased serum VEGF levels. These antiangiogenic 
effects of imatinib, and other TKIs, have been reviewed by others 
(36). Only occasional responses to imatinib monotherapy have 
been observed in non-GIST sarcoma patients (56).
Sunitinib and regorafenib are both FDA-approved therapies 
for advanced GIST (second-, and third-line treatment, respec-
tively) after failure to respond to imatinib. Their effects on tumor 
stroma, including angiogenesis, have not been clearly separated 
from the anti-proliferative effects on tumor cells (57–59).
Therapies with immune-Modulating 
effects
Several cancer therapies in sarcoma may have direct or indirect 
effects on the immune system (38, 60, 61). Chemotherapy 
can, e.g., induce immunogenic cell death in tumors, block the 
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immunosuppressive functions of myeloid-derived suppressive 
cells and likely lead to a more pronounced anti-tumor response. 
Trabectedin, approved by the European Medicines Agency 
(EMA) for second-line treatment of advanced STS, is an example 
of a chemotherapeutic agent, with the additional ability to induce 
apoptosis selectively in monocytes/macrophages (62).
The EMA approved the immunostimulant mifamurtide in 
2009 for the use in high-grade non-metastatic osteosarcoma in 
combination with postoperative chemotherapy. The treatment 
was shown to significantly improve 6-year overall survival 
from 70 to 78% (63). Additional studies on the therapeutic 
efficacy are however warranted (2, 63, 64). Mifamurtide is 
reported to have its mechanism of action on macrophages and 
monocytes.
An illustrative example of a targeted therapy with immune-
modulating side effects is imatinib treatment in advanced GIST, 
where an immunologic interferon-γ response has been associated 
with long-term survival (65). The antiangiogenic, anti-tumor, 
and immunostimulating roles of interferons have been reviewed 
elsewhere (66).
Denosumab is an FDA-approved monoclonal antibody 
directed against RANKL, which is expressed by the neoplastic 
cells in giant-cell tumor of bone (67). Osteoclasts, their precur-
sors and reactive osteoclast-like giant cells express the receptor 
RANK. RANKL–RANK signaling contributes to osteoclast 
formation, osteolysis, and tumor growth. This type of tumor is 
often benign, but with unpredictable behavior.
Targeted Therapies Under investigation
Ongoing and future studies will reveal to what extent current 
targeted therapies under investigation have anti-tumor effects 
associated with the tumor microenvironment. Selected examples 
include the antiangiogenic TKIs sunitinib and cediranib with 
potential anti-tumor activity in ASPS, a malignancy associated 
with oncogenic MET signaling, pro-angiogenic factors, and 
inflammatory components (38, 68–70). Abundant VEGF expres-
sion has been confirmed. Sunitinib has also shown activity in 
solitary fibrous tumors (71). In the latter study, all cases were 
positive for PDGFRβ and/or VEGFR2.
Sorafenib is another widely used TKI with potential activity 
in subsets of sarcomas, either as mono- or combination therapy 
(72). Anti-tumor effects are believed to occur by several molecu-
lar mechanisms including inhibition of RAF, VEGFRs, PDGFRs, 
and KIT. Recently, the early results from a sorafenib phase II 
trial with locally advanced and metastatic chordoma patients 
were presented and compared with the results from two previous 
chordoma phase II trials with imatinib and lapatinib, respectively 
(73). Response rates were modest. Chordomas frequently express 
growth factor receptors, such as PDGFRs and EGFRs (74), and 
VEGF expression has been confirmed (75, 76).
An example of an antibody-based targeted therapy with 
promising activity is the use of olaratumab, an anti-PDGFRα 
monoclonal antibody, in combination with doxorubicin in 
advanced STS (abstract 10501, ASCO Annual meeting 2015). In 
a randomized phase Ib/II study, an improvement of 10.3 months 
in overall survival was achieved compared to doxorubicin alone 
(HR = 0.44, p = 0.0005).
It is yet too early to say whether novel immune-modulating 
therapies will be of therapeutic value in sarcoma. Immune check-
point inhibitors have emerged as a promising therapy in other 
tumor types and are currently being tested in sarcoma. T-cell 
receptor-based gene therapy directed against tumor-specific 
antigens is another type of treatment with promising activity in 
synovial sarcoma (77).
COnCLUDinG ReMARKS
Treatment options are today limited for many sarcoma patients. 
The infiltrative growth pattern of many sarcomas makes complete 
tumor resection with negative margins difficult. Distant metasta-
ses are often present already at diagnosis. Further preclinical and 
clinical studies are clearly needed to identify novel therapeutic 
targets.
The future directions of sarcoma diagnosis, therapy and follow-
up are likely to rely more on tumor-specific biology. Careful moni-
toring of individual tumor genetics and gene/protein expression 
patterns is predicted to be essential. Therapy-adapted screening 
methods and standard criteria for tumor response assessment 
beyond the response evaluation criteria in solid tumors (RECIST) 
need to be further developed. Useful biomarkers, stromal compo-
nents, and microenvironmental targets of importance for disease 
progression largely remain to be identified within the new era of 
personalized medicine.
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